ILIAS Biologics Secures Phase 1 Results of Exosome Treatment and Announces International Journal of Academic Journal

ILIAS Biologics Inc. explained that the comprehensive analysis of the safety and tolerability data of 'ILB-202' confirmed through the final clinical study report (CSR) for the lead pipeline exosome therapeutic, 'ILB-202,' indicates a higher expected safety compared to existing anti-inflammatory treatments. Additionally, ILIAS Biologics Inc. announced that their non-clinical research results for the clinical application of engineered exosomes designed to deliver therapeutic proteins into cells were published in the June online edition of the prestigious international journal 'Stem Cells Translational Medicine.' Please check out the link below for more information. News Link PREV LIST NEXT Ilias Company name ILIAS Biologics Inc. CEO Chulhee Choi Corporate registration number 161-86-00309 ADDRESS 40-20 Techno 6-ro, Yuseong-gu, Daejeon, 34014, Republic of Korea TEL 042-863-4450 FAX 042-863-4499 ⓒ 2021 ILIAS Biologics Inc. ALL RIGHTS RESERVED.

The release as fetched from its publisher. iliasbio.com ↗